Pirfenidone in Treating Young Patients With Neurofibromatosis Type I and Recurrent or Progressive Plexiform Neurofibromas

This study is currently recruiting participants.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Neurofibromatosis Type 1 (nf1)
			Precancerous/Nonmalignant Condition
2		Additional conditions recognized in this trial
			Neurofibroma
			Neurofibroma, Plexiform
			Neurofibromatoses
			Neurofibromatosis 1
			Precancerous Conditions
3		More general conditions related to this trial
			Genetic Diseases, Inborn
			Heredodegenerative Disorders, Nervous System
			Neoplasms
			Neoplasms by Histologic Type
			Neoplasms, Nerve Tissue
			Neoplastic Syndromes, Hereditary
			Nerve Sheath Neoplasms
			Nervous System Diseases
			Nervous System Neoplasms
			Neurocutaneous Syndromes
			Neurodegenerative Diseases
			Neuromuscular Diseases
			Peripheral Nervous System Diseases
			Peripheral Nervous System Neoplasms
4		Interventions listed in this trial
			pirfenidone
5		More general drug interventions related to this trial
			Analgesics
			Analgesics, Non-Narcotic
			Anti-Inflammatory Agents
			Anti-Inflammatory Agents, Non-Steroidal
			Antineoplastic Agents
			Antirheumatic Agents
			Central Nervous System Agents
			Peripheral Nervous System Agents
			Pharmacologic Actions
			Physiological Effects of Drugs
			Sensory System Agents
			Therapeutic Uses
6		Sponsors listed in this trial
			National Cancer Institute (NCI)